Vertex Presents at Goldman Sachs Healthcare Conference; Reiterates Growth Strategy Amid Launch Execution Concerns

What happened

Vertex management presented at the 2026 Goldman Sachs Healthcare Conference, reiterating confidence in its cystic fibrosis franchise and the long-term potential of newer launches Journavx and Casgevy. However, the presentation did not address the persistent disconnect between rising prescription volumes for Journavx and Casgevy and the actual revenue capture, which remains far below consensus expectations. With Q3 2025 Journavx revenue of just $20M despite over 300K prescriptions, and Casgevy infusions still in the dozens, the market's hope for near-term diversification remains unsupported by execution. The company's elevated cost base, guided at $5.0–5.1B non-GAAP operating expenses for 2025, continues to pressure margins without a proportional top-line uplift from these new assets. This event introduces no new catalysts or data that would alter the fundamental mismatch between valuation and operational reality.

Implication

Vertex's Goldman Sachs presentation offered no corrective data on the weak revenue conversion of Journavx and Casgevy, nor any indication that the $5B+ cost base will improve earnings growth. Investors should view this as a reaffirmation of the thesis that the stock's ~33x P/E premium relies on unvalidated assumptions about pipeline revenue. With CF growth steady but mid-single-digit, and new launches subscale, the risk of multiple compression outweighs any upside from conference cheerleading. We see no reason to alter our POTENTIAL SELL rating and recommend trimming on any strength above $520, with a re-assessment window of 6-12 months pending demonstrable improvements in net revenue per script for Journavx and Casgevy throughput.

Thesis delta

The Goldman Sachs presentation does not alter our thesis. We continue to see asymmetric risk from the gap between market pricing and the economic conversion of Vertex's non-CF launches. Until quarterly revenues from Journavx and Casgevy show material acceleration, the premium valuation remains vulnerable.